Close Menu

NEW YORK – Array Genomics is in the midst of rolling out its microarray-based test for staging and grading bladder cancer based on urine samples. The molecular diagnostics company received a CE-IVD mark for the assay, called BCA-1, in June, and launched the test in October.

While Array Genomics has seen some initial demand for the test, which is currently paid for out of pocket, the company is keen to support more studies that will raise the profile of the firm and its product and perhaps see it adopted into European urology guidelines.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.

Mar
17
Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.